Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy

BACKGROUND: We conducted a phase I/II clinical trial to evaluate the efficacy of eribulin and olaparib in a tablet form (EO study) for triple-negative breast cancer (TNBC) patients. We hypothesized that somatic BRCA mutations and homologous recombination repair (HRR)-related gene alterations might a...

Full description

Bibliographic Details
Main Authors: Akihiko Shimomura, Kan Yonemori, Masayuki Yoshida, Teruhiko Yoshida, Hiroyuki Yasojima, Norikazu Masuda, Kenjiro Aogi, Masato Takahashi, Yoichi Naito, Satoru Shimizu, Rikiya Nakamura, Akinobu Hamada, Hirofumi Michimae, Jun Hashimoto, Harukaze Yamamoto, Asuka Kawachi, Chikako Shimizu, Yasuhiro Fujiwara, Kenji Tamura
Format: Article
Language:English
Published: Elsevier 2019-10-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523319302037

Internet

http://www.sciencedirect.com/science/article/pii/S1936523319302037

Similar Items